Allergy Therapeutics (LON:AGY) Announces Earnings Results

Allergy Therapeutics (LON:AGY) released its quarterly earnings results on Tuesday. The company reported GBX (0.38) earnings per share (EPS) for the quarter, Digital Look Earnings reports. The firm had revenue of GBX 3,628 million for the quarter. Allergy Therapeutics had a negative net margin of 72.91% and a positive return on equity of 227.10%.

Allergy Therapeutics Stock Performance

AGY remained flat at GBX 10.30 during midday trading on Thursday. The company’s stock had a trading volume of 71,346 shares, compared to its average volume of 280,355. The company has a debt-to-equity ratio of -213.13, a quick ratio of 1.48 and a current ratio of 1.28. The firm has a fifty day simple moving average of GBX 10.96 and a two-hundred day simple moving average of GBX 10.04. The stock has a market capitalization of £652.25 million, a PE ratio of -12.26, a P/E/G ratio of -30.70 and a beta of 0.83. Allergy Therapeutics has a 12-month low of GBX 5 and a 12-month high of GBX 12.10.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.